Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $6.30 million. The enterprise value is $604,983.
| Market Cap | 6.30M |
| Enterprise Value | 604,983 |
Important Dates
The next estimated earnings date is Friday, July 26, 2024, after market close.
| Earnings Date | Jul 26, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 2.71 million shares outstanding. The number of shares has increased by 14.61% in one year.
| Shares Outstanding | 2.71M |
| Shares Change (YoY) | +14.61% |
| Shares Change (QoQ) | +1.59% |
| Owned by Insiders (%) | 21.90% |
| Owned by Institutions (%) | 41.37% |
| Float | 1.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.63 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 4.06 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.17, with zero debt.
| Current Ratio | 4.17 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0.57 |
Financial Efficiency
Return on equity (ROE) is 1.50% and return on invested capital (ROIC) is -137.77%.
| Return on Equity (ROE) | 1.50% |
| Return on Assets (ROA) | 1.20% |
| Return on Capital (ROIC) | -137.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $149,000 |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.10% in the last 52 weeks. The beta is 1.84, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | -44.10% |
| 50-Day Moving Average | 2.72 |
| 200-Day Moving Average | 3.01 |
| Relative Strength Index (RSI) | 44.63 |
| Average Volume (20 Days) | 7,431 |
Short Selling Information
The latest short interest is 14,532, so 0.54% of the outstanding shares have been sold short.
| Short Interest | 14,532 |
| Short Previous Month | 17,835 |
| Short % of Shares Out | 0.54% |
| Short % of Float | 1.35% |
| Short Ratio (days to cover) | 11.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.67M |
| Pretax Income | 149,000 |
| Net Income | 149,000 |
| EBITDA | -197,000 |
| EBIT | -197,000 |
| Earnings Per Share (EPS) | -$0.43 |
Balance Sheet
The company has $5.70 million in cash and no debt, giving a net cash position of $5.70 million or $2.10 per share.
| Cash & Cash Equivalents | 5.70M |
| Total Debt | n/a |
| Net Cash | 5.70M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 9.92M |
| Book Value Per Share | 3.66 |
| Working Capital | 4.57M |
Cash Flow
| Operating Cash Flow | -16.90M |
| Capital Expenditures | n/a |
| Free Cash Flow | -16.90M |
| FCF Per Share | -$6.78 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYCN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.61% |
| Shareholder Yield | -14.61% |
| Earnings Yield | 2.36% |
| FCF Yield | -268.24% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 16, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | May 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |